Bristol-Myers Squibb Company (BMY) closed at $61.12 on October 21, 2026, down 0.9% from the previous close, on volume of 6,651,083 shares (30-day average 12,842,155).
Data as of October 21, 2026.
TipRanks (Tue, 20-Oct 7:00 AM ET)
Bristol Myers to bring 12 oral presentations and nearly 60 oncology disclosures to ESMO 2026
Market Chameleon (Mon, 19-Oct 4:50 AM ET)
Business Wire (Mon, 19-Oct 6:59 AM ET)
TipRanks (Fri, 16-Oct 9:50 PM ET)
Market Chameleon (Mon, 12-Oct 3:30 AM ET)
Business Wire (Mon, 12-Oct 6:55 AM ET)
Business Wire (Mon, 12-Oct 6:50 AM ET)
Business Wire (Thu, 8-Oct 6:59 AM ET)
Business Wire (Thu, 1-Oct 6:59 AM ET)
Bristol Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Bristol derives close to 70% of total sales from the US, showing a higher dependence on the US market than most of its peer group.
Bristol-Myers Squibb Company trades on the NYSE stock market under the symbol BMY.
As of October 21, 2026, BMY stock price declined to $61.12 with 6,651,083 million shares trading.
BMY has a beta of 0.03, meaning it tends to be less sensitive to market movements. BMY has a correlation of 0.00 to the broad based SPY ETF.
BMY has a market cap of $124.79 billion. This is considered a Large Cap stock.
Last quarter Bristol-Myers Squibb Company reported $13 billion in Revenue and $2.04 earnings per share. This beat revenue expectation by $1 billion and exceeded earnings estimates by $.43.
In the last 3 years, BMY traded as high as $68.64 and as low as $39.35.
The top ETF exchange traded funds that BMY belongs to (by Net Assets): VTI, SCHD, VOO, IVV, SPY.
BMY has outperformed the market in the last year with a price return of +46.0% while the SPY ETF gained +16.3%. However, in the short term, BMY had mixed performance relative to the market. It has underperformed in the last 3 months, returning +2.6% vs +4.4% return in SPY. But in the last 2 weeks, BMY shares have fared better than the market returning +2.6% compared to SPY -0.8%.
BMY support price is $60.36 and resistance is $63.01 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that BMY shares will trade within this expected range on the day.
